Lupin Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each fully paid up for the Financial Year ended March 31, 2026.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited reported strong FY2026 results with consolidated revenue growing 23% to ₹279.6 billion from ₹227.1 billion. Profit after tax surged 62% to ₹53.6 billion on consolidated basis and 60% to ₹63.7 billion on standalone basis. The Board recommended a dividend of ₹18 per share (900% of face value), up from previous years. Key exceptional items included ₹5.8 billion cumulative provision for antitrust litigation, ₹8.5 billion settlement with Astellas for Mirabegron ER tablets, and ₹512 million for new labour codes implementation. The company completed acquisitions of VISUfarma B.V. (€192.8 million) and Renascience Pharma UK during the year. Auditor B S R & Co. LLP issued an unmodified opinion, confirming clean financials.
Strong profitability growth and clean audit opinion are positive signals for shareholders. The significant 23% revenue growth and 60%+ PAT growth demonstrate operational strength, though exceptional litigation items and settlements create some one-time noise in earnings.